Who is sponsoring NCT00849368?

NCT00849368 is sponsored by University of Zurich.

What condition does NCT00849368 study?

NCT00849368 studies Inflammatory Bowel Disease.

What drugs are being tested in NCT00849368?

Interventions: Azathioprine / Allopurinol.

What is the status of NCT00849368?

NCT00849368 is currently COMPLETED.

Last reviewed 2012-02-06 · How we verify

Dose-effect Relationship Between Allopurinol, Azathioprine and 6-thioguanine Nucleotide Levels (6-TGN) in Inflammatory Bowel Disease Patients.

NCT00849368 Phase 1 COMPLETED

Main Study Objectives: The study is conducted to * evaluate the minimal allopurinol and azathioprine doses that, in combination, produce therapeutic 6-TGN levels * evaluate the safety and tolerability of the different allopurinol/azathioprine dose levels * assess if concomitant allopurinol affects TPMT activity * assess the clinical efficacy of concomitant allopurinol-azathioprine therapy in the included patients

Details

Lead sponsor	University of Zurich
Phase	Phase 1
Status	COMPLETED
Enrolment	6
Start date	2009-01
Completion	2011-09

Conditions

Inflammatory Bowel Disease

Interventions

Azathioprine / Allopurinol

Primary outcomes

Pharmacokinetics: Quantification of trough concentrations of 6-TGN and 6-MMPN in erythrocytes using HPLC at each dose level. — three times per cycle

Countries

Switzerland